Clinical trial • Phase I • Immunology|Dermatology
KLR-003 for Psoriasis
Phase I trial of KLR-003 for Psoriasis. 182 participants.
Overview
- Trial Therapeutic Area
- Immunology|Dermatology
- Trial Disease
- Psoriasis
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 23-03-2026
- First CTIS Authorization Date
- 30-04-2026
Trial design
Phase I trial across 1 site in Netherlands.
- Target Sample Size
- 182
Recruitment
- Planned Sample Size
- 182
- Recruitment Window Months
- 35
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 182
Netherlands
- Earliest CTIS Part Ii Submission Date
- 22-04-2026
- Latest Decision Or Authorization Date
- 30-04-2026
- Processing Time Days
- 8
- Number Of Sites
- 1
- Number Of Participants
- 182
Sites
- Site Name
- Centre for Human Drug Research
- Department Name
- Dermatology
- Contact Person Name
- Robert Rissmann
- Contact Person Email
- clintrials@chdr.nl
Sponsor
Primary sponsor
- Full Name
- Klear Bio Inc.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- KLR-003
- First In Human
- Yes
Related trials
Other published trials that may interest you.